Apyx Medical Corporation filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 19, 2026, covering shares of common stock issuable under a new equity plan and an individual inducement award.

Key Highlights

  • Two share pools registered: 4,000,000 shares issuable under the Apyx Medical Corporation 2026 Share Incentive Plan, plus 100,000 shares tied to a separate inducement award.
  • Inducement award recipient: John Featherstone received a non-qualified stock option as a material inducement to his commencement of employment, according to the filing.
  • Inducement award basis: The 100,000-share option was granted outside the company's equity compensation plans in reliance on Nasdaq Listing Rule 5635(c)(4), the filing states.
  • Option agreement date: The Stock Option Agreement with John Featherstone is stated as effective August 4, 2025.
  • Common stock par value: Shares registered carry a par value of $0.001 per share, as disclosed in the filing.
  • Company classification: Apyx Medical Corporation identified itself as a smaller reporting company on the registration statement cover.

Apyx Medical's S-8 Covers 2026 Plan Shares and Featherstone Option

Apyx Medical Corporation (NASDAQ:APYX), a Delaware-incorporated company headquartered at 5115 Ulmerton Road, Clearwater, Florida, filed a Form S-8 registration statement on November 19, 2026, to register shares of its common stock in connection with two separate equity arrangements. According to the filing, 4,000,000 shares are issuable under the Apyx Medical Corporation 2026 Share Incentive Plan, which the filing notes was incorporated by reference to an exhibit filed with an August 7, 2026 Current Report on Form 8-K.

Separately, the filing discloses that 100,000 shares of common stock are issuable upon the exercise of a non-qualified stock option granted to John Featherstone. The filing describes this grant as "a material inducement to his commencement of employment with the Company," made outside of the company's existing equity compensation plans. The company states it relied on Nasdaq Listing Rule 5635(c)(4) for this inducement grant. The Stock Option Agreement is stated as effective August 4, 2025.

The registration statement incorporates by reference the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed March 10, 2026, as well as Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, filed on May 7, 2026, August 6, 2026, and November 5, 2026, respectively. The filing also notes that the company has obtained liability insurance coverage for its directors and executive officers with respect to actions arising out of their performance of duties.

What Was Disclosed

Apyx Medical Corporation registered a combined total of 4,100,000 shares of $0.001 par value common stock via Form S-8 on November 19, 2026, covering both its 2026 Share Incentive Plan and a standalone inducement stock option awarded to John Featherstone.